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ABSTRACT
Visualization of NIR-fluorescence 
labeled Affibody and Trastuzumab in 
HER2 overexpressed Gastric Cancer
Kyoungyun Jeong
Seoul National University College of Medicine
Introduction: Human Epidermal Receptor-2(HER2) is highly 
overexpressed in many kinds of cancers with a poor prognosis. Recently, 
near-infrared (NIR) fluorescence-based imaging is a growing field for 
both pre-clinical and clinical application. We developed molecular probe 
for in vivo imaging of HER2 using prospective NIR fluorescence, 
IRDye800CW. This study aimed to image HER2 overexpression in 
gastric cancer.
Methods: The human gastric carcinoma NCI-N87 and SNU601 and two 
patients-derived xenograft (PDX) cases were chosen by the level of 
HER2 expression. We obtained HER2-target probe under Click reaction. 
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Trastuzumab (Roche, USA) and HER2-target affibody (Affibody AB, 
Sweden) were conjugated with IRDye800CW. The resulting conjugates 
were characterized by Reichart and Biacore affinity measurements. 
Female BALB/c nude (6 to 8 weeks old) mice were subcutaneously 
implanted with gastric cancer cell lines and PDX tissues. Fluorescence 
intensity was quantified by a Lumina II (Perkin Elmer) and laparoscopic 
NIR camera (InTheSmart, Seoul, Korea).
Results: Trastuzumab-IRDye800CW showed higher affinity to HER2 
(K(D) = 2.093(3)pM) than unlabeled trastuzumab(K(D) = 25.75pM). 
This probe showed significantly high signal in HER2 positive gastric 
cancer cell mouse tumor model, while no or low signal retention was 
observed in HER2 negative group. On the other hand, HER2-target 
affibody-IRDye800CW showed insufficient affinity (K(D) = 4.71 nM)
compared to both unlabeled affibody(K(D) = 1.42 nM) and trastuzumab 
molecules. The renal clearance of HER2-target affibody conjugated with 
IRDye800CW was so fast that we could not detect the signal.
Conclusion: Our results suggest that trastuzumab conjugated with 
IRDye800CW can be a feasible tool to monitor HER2 status in pre-
clinical cancer imaging. Moreover, this probe can provide complementary 
means for assessment of HER2 expression in gastric cancer patients
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INTRODUCTION
Visualizing the lesion of gastrointestinal tract with minimally 
invasive procedure can be effective guidance to physicians. Image-
guided biopsy and image-guided surgery can be option for 
precision medicine, which enables surgeons to examining the 
appropriate region during the operation and gastroscopy.(1, 2)
There are several kinds of image-guided surgery using various 
types of molecules such as radioisotope, near-infrared. 
Radioisotope can generate genetic mutation, damages tissues(3, 4). 
Compare to this, near-infrared fluorescence guided surgery is most 
effective and non-invasive, real-time method.(5, 6) Because of 
ability of the fluorescent to bind high proportion of plasma proteins 
and its effectiveness for navigating sentinel lymph node, ICG is 
commonly used in these days in gastric cancer surgery.(7-9)
However, ICG is limited by its aqueous instability and rapid 
degradation, fast dispersion,(10, 11) while IRDye800CW have 
excellent water solubility, low auto-fluorescent background. 
Considering of auto-fluorescence, absorbance of the light and the 
scattering areas, it is more attractive that using near-infrared (NIR) 
fluorescence, IRDye800CW, to navigate deeper-located tumor with 
sensitivity and accuracy.(12-14) In the spectrum of 700-900nm, 
auto- fluorescence signals are minimized, and there is the lowest 
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tissue absorption of light, resulting in optimal tissue 
penetration.(15-17) Therefore, IRDye800CW is a fluorescent that 
is expected to be widely use in clinical practice.
Cancer specific imaging or targeted imaging of near-infrared dye is 
specific delivery of cancer tracer to tumor cells for guiding 
surgeons to reach right lesion of tumor during surgery, which has 
huge advantage of sighting of deep penetration of signals and high 
sensitivity compared to virtual dyes.(18) Azais H et al. developed a 
small ligand like folate linked to a fluorophore, which targets the 
folate-α receptor in ovarian cancer patients specifically.(19) To 
distinguish tumor cells, near-infrared based cancer specific 
molecules have been developed to target molecular markers such as 
membrane proteins. Tumor specific markers should be more 
expressed in tumor cells than normal cells and/or monopolistic for 
tumor cells. 
The transmembrane glycoprotein HER2 is overexpressed in many 
types of cancer, especially breast and gastric cancers. The 
overexpression of this peptide has been correlated with poor 
prognosis.(20, 21)According to ToGa trial, doctors characterize 
HER2 positive and negative by identifying IHC and FISH level of 
patients and prescribe adjuvant chemotherapy with trastuzumab to 
people who have amplified HER2(22). 
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Numerous antibody mimetics or fragments are used to be modified 
as a tracer. One of the smallest peptides of antibody mimetics is 
affibody (Affibody AB, Sweden). The size of the HER2-target-
affibody is 6 ~ 7kDa and it does not bind same structure as 
trastuzumab. Since it is very small compared to monoclonal 
antibody, trastuzumab (Roche, USA) and it does not share the same 
region of epitope as trastuzumab, many researchers tried to modify 
this small molecule as a tumor targeting probe. Many previous 
studies were conducted with the conjugation of small molecules(23, 
24). Antibodies are the most widely used types of targeting agent 
today, and trastuzumab is a monoclonal antibody of HER2 and this 
antibody can be modified as a tracer of HER2. The large size of 
antibody molecules can, however, lead to poor solid tumor 
penetration and slow elimination from the circulation. To avoid 
these problems, smaller antibody constructs, such as Fab’s, 
minibodies and scFv, affibodies have successfully been made. 
Affibody molecules are stable three-helix molecules comprising 58 
amino acids derived from a domain of staphylococcal protein A with 
13 positions randomized. As affibody molecules contain no 
disulphite bonds, they can easily be produced in the cytoplasm and 
can be chemically synthesized. In this study, we focus on the 
visualizing of HER2 of gastric cancer by antibody and/or affibody 
and examining the in vivo targeting potential of the construct and 
demonstrate its utility as a tumor-imaging agent. 
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There are variety of studies which specifically image HER2 in 
different kinds of cancer cells. The use of radiolabeled HER2 
specific antibodies(25-27) and fragments(28-32) for imaging 
HER2 expression has been reported. Since the HER2 target peptide 
conjugated with near-infrared fluorescence can non-invasively 
attach tumor cell and can penetrate tissue with low backgrounds, 
people have synthesized various types of probe using antibodies(33, 
34) and fragments such as affibodies(35). 
However, so far, no study has yet been done in gastric cancer with 
near-infrared fluorescence. We compared which near-infrared 
fluorescent conjugated peptide can well detect HER2 expression in 
gastric cancer. 
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Purpose of this study
We hypothesized that fluorescence labeled HER2-target affibody 
can visualize HER2 overexpressed gastric cancer more effectively 
than labeled with HER2 monoclonal antibody, trastuzumab.
Therefore, the aim of this study is to visualize HER2 
overexpression in gastric cancer and to compare those HER2 
specific fluorescent tracer. Through this investigation, we would 
like to use this modified molecule as a diagnostic and monitoring 





Four human gastric cancer cell lines, SNU-216, SNU-601, 
NCI-N87 and SNU-638 cells were obtained from the Korean Cell 
Line Bank (Seoul, Korea) and maintained in Rosewell Park 
Memorial Institute media (RPMI 1640) (Welgene, Daegu, Korea) 
with 10% Fetal bovine serum (FBS, Gibco, Invitrogen, UK) and 2% 
penicillin-streptomycin (Gibco, Invitrogen, UK). All cell lines were 
cultured and maintained in the conditions of 37℃ in a 5% CO2 
humidified environment.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from cell lines using Trizol reagent 
(Invitrogen, Carlsbad, USA). cDNA was synthesized to analyze 
mRNA expressions using a TOP script cDNA synthesis kit 
(Enzynomics, Daejeon, Korea) according to the manufacturer’s 
protocols. The expression level of HER2 was measured using SYBR 
Green Master Mix (Applied Biosystems, Carlsbad, CA, USA) by 
normalizing to GAPDH housekeeping gene. Primers are indicated in 
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Table 1. All the reaction were performed and analyzed by 
comparative △△Ct methods using Step One Plus Real-Time PCR 
system (Applied Biosystems, Carlsbad, CA, USA).








Cells were grown to 80% confluence and washed with cold 
PBS and lysed with RIPA buffer (ThermoFisher Scientific, MA, 
USA) plus protease inhibitor cocktails (Roche, Swiss). Proteins 
were isolated from cell lysates, and the lysate was collected by 
centrifugation at 15,000 RPM for 15min at 4℃ and the protein 
concentration was measured by bicinconinic acid (BCA) assay 
(Thermo Scientific, MA, USA). Lysate containing 25ug of protein 
was seperated by sodium dodecyl sulfate-polyacrylamide gel 
(SDS-PAGE), Bolt 4-12% Bis-Tris Plus gel, and transferred to a 
polyvinylidene difluoride (PVDF) membrane(Millapore, Watford, 
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UK). The membrane was probed with GAPDH(1:3000 dilution, 
Abcam, UK, cat. ab8245 ) to ensure equal protein loading, followed 
by blocking with 5% skim milk and incubation with primary antibody; 
HER2/neu(1:1,000 ; Cell signaling, USA, cat. 2165). After wasing 
and incubating with HRP-conjugated secondary antibodies; mouse 
IgG(1:3,000; Cell signaling technology, USA, cat. 7076P2) and 
rabbit IgG(1:3,000; Cell signaling technology, USA, cat. 7074). The 
membrane was washed with tris-buffered saline and tween 
20(TBS-T) and visualized with Enhanced chemiluminescent (ECL) 
HRP substrate (ThermoFisher Sci. cat. 34577), imaged by 
ChemiDoc(Bio-Rad, USA).
Synthesis of HER2-specific probe
The IRDye800CW azide infrared dye(Li-COR Bioscience, 
USA) contain a azide that allows for site-specific labeling. 
Dibenzocyclooctyne group (DBCO)-PEG4-maleimide were 
purchased from Futurechem. Co., Ltd (Korea). PD-10 column were 
purchased from GE Healthcare(USA). Trastuzumab(Roche, Swiss) 
and HER2-target affibody(Affibody AB, Sweden) were conjugated 
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with IRDye800CW under click chemistry. All of the fluorescently 
labeled protein samples were aliquoted and sotred in the dark 
fridger at -20°C. 
Synthesis of Trastuzumab-DBCO (TRZ-DBCO)
4 ㎕ of 0.3 M ethylenediaminetetraacetic acid(Sigma-
Aldrich, MO, USA) in DW, 4 ㎕ of 1 M sodium bicarbonate(Sigma-
Aldrich, MO, USA) in distilled water(DW) and 5 ㎕ 1.5 M β-
mercaptoethanol(Thermo Scientific, MA, USA) in DW were added 
to trastuzumab solution for injection(2 mg/96 ㎕, 13.8 nmol). The 
mixture was incubated at 37℃ for 1 hr and purified using PD-10 
column with PBS. To this 2 ml of TRZ-SH solution in PBS, 13.4 ㎕
of DBCO-PEG4-Maleimide in dimethyl sulfoxide (DMSO, 248.4 
nmol) was added and incubated at 37℃ for 1.5 hr. The reaction 
mixture was purified using PD-10 column with PBS to give 13.5 
nmol of Trastuzumab-DBCO (TRZ-DBCO).
Synthesis of Trastuzumab-IRDye800CW (TRZ-IRDye)
IRDye 800CW Azide in water (0.14 mg/13.7 ㎕, 108 nmol) 
was added to 2 ml of TRZ-DBCO (13.5 nmol) solution in PBS. The 
mixture was vortexed at 38°C for 3 hrs and purified using PD-10 
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column with PBS to give 13.2 nmol of Trastuzumab-IRDye800CW
(TRZ-IRDye).
Synthesis of Affibody-DBCO (ABY-DBCO)
Affibody (0.5 mg, 35.7 nmol) was dissolved in 0.5 ml PBS 
and this solution was added to 298 ㎕ 0.1 M Dithiothreitol (DTT, 
Thermofisher sci. USA). The mixture was incubated at 37℃ for 1 
hr and purified using PD-10 column with PBS. To this 2 ml of 
ABY-SH solution in PBS, 19.6 ㎕ of DBCO-PEG4-Maleimide in 
DMSO (363.3 nmol) was added and incubated at 37℃ for 1.5 hr. 
The reaction mixture was purified using PD-10 column with PBS to 
give 35.0 nmol of Affibody-DBCO (ABY-DBCO).
Synthesis of Affibody-IRDye800CW (ABY-IRDye)
IRDye 800CW Azide in water (0.37 mg/36.4 ㎕, 287 nmol) 
was added to 2 ml of ABY-DBCO (35.0 nmol) solution in PBS. The 
mixture was vortexed at 38°C for 3 hrs and purified using PD-10 




2 mCi (0.5 ml) of 111InCl3 solution was dissolved in 0.5 ml 
sodium acetate buffer (pH=5.6). The mixture was added to 7.5 ㎕
of NOTA-PEG3-N3 (11.25 nmol) solution in DW. The mixture was 
incubated at 70°C for 10 min to give 2 mCi of 111In-NOTA-PEG3-
N3 (11.25 nmol). The radiolabeling efficiency (LE = 100 %) was 
determined using ITLC-SG after the radiolabeling with 0.1 M citric 
acid as the mobile phase. The Rf of 111In-NOTA-PEG3-N3 = 0.6; 
Rf of free radioisotope = 0.9–1.0. 
Synthesis of 111In-Affibody (111In-ABY)
2 mCi (1 ml) of 111In-NOTA-PEG3-N3 (11.25 nmol) 
solution in sodium acetate buffer was added to 0.36 ml of Afb-
DBCO (11.25 nmol) solution in PBS. The mixture was vortexed at 
38°C for 3 hrs to give 2 mCi of 111In-Afb. The radiolabeling 
efficiency (LE = 100 %) was determined using ITLC-SG with 0.1 
M citric acid as the mobile phase. The Rf of 111In-Afb = 0.2.
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Stability of the near-infrared probes
The fluorescence stability of Affibody-IRDye800 (100 
μg/mL) and Trastuzumab-IRDye800 (100 μg/mL) was 
determined using a fluorescence spectrophotometer, Varioskan LUX 
microplate reader (Thermofisher, USA). The aqueous solutions 
were prepared and placed in the 96 well black plate(SPL Life 
Science, Korea). The fluorescence emission spectra were measured
at an excitation wavelength of 720 nm. The maximum fluorescence 
(λem = 840 nm) intensity of each sample at a given time was
normalized by the corresponding fluorescence emission. The 
average normalized fluorescence intensities for each triplicate 
experiment were plotted. 
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Cell viability assay
To evaluate the cytotoxicity of trastzuaumab molecules 
and/or affibody molecules, cell viability assays were performed in 
SNU-601, NCI-87 cell line using Cell Counting Kit-8 (Dojindo 
Laboratories, Kumamoto, Japan) at absorbance 450nm for 48hr. 
Cells were plated in 96-well flat bottomed plates at a density of 
5×103 per 100uL growth medium in quintuplicate. Affibody and 
trastuzumab molecules were dissolved in PBS. Cells were incubated 
for 48 h after treatments at increasing concentrations 10uM. 
Luminoskan Ascent(ThermoFisher Sci. USA) was used to measure 
luminescence.
Binding affinity assay
Surface Plasmon resonance experiments were done on a 
Reichert SR7500C (Reichaert Technologies, USA) and Biacore 
T200 instrument (GE Healthcare, Sweden). For HER2/FC (R&D 
Systems, NE, USA), 1,100 relative unit (RU) protein was captured 
on the protein modified PEG sensor ship via an immobilization 
capture wizard. To verify the kinetic data, we evaluated using 
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software Scrubber2 and Control software version 2.0.1 & BIA
evaluation software version 3.0 for each Reichert and Biacore result.
Immunofluorescence
Prepare coating coverslips in 6-well dish with poly-L-
lysine (Sigma aldrich, cat. 25988) and plate 1 x 104cells. After the 
confluency of cultured dish reach ~80%, apply 4% 
paraformaldehyde solution (Thermo Scientific, MA, USA) for 10min, 
wash cells in PBS containing Triton X-100(Sigma-Aldrich, MO, 
USA) and 0.05% Tween20. Permealize cell with 0.5% Triton and 
PBS for 20min in room temperature. After remove the solution, 
apply blocking buffer (PBS, TritonX-100, Tween, 1% of BSA) for 
30minutes in room temperature. Add near-infrared dye conjugated 
with HER2-target peptides overnight to cells. Wash with PBS 
several times, drop 20ul of DAPI ProLongGold (Invitrogen, CA, 
USA) Cultured cells were scanned and verified using established in 
vitro fluorescence methods with ImageXpress (Molecular Devices, 
San Jose, CA, USA). 
In vivo near-infrared imaging experiments
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Each cell line was harvested using Trypsin-EDTA(Gibco) 
and re-suspended at 1x106 cells in 0.1 mL of 50% of growth factor 
reduced Matrigel (BD Bdioscience, USA, cat. 80712368) kept at 
4°C and injected subcutaneously into the right flank of 6-8 
weeks-old female BALB/c nu/nu mice (Orient Bio., Sungnam, 
Korea). Patient-dervied xenograft(PDX) tissues were chopped and 
implanted to 6-8 weeks BALB/C nu/nu mice by using trocar to 
establish tumor xenograft models. 
Tumor size was measured using calipers twice every week, 
and the tumor volume was calculated by 1/2 × lenghth (L) ×
width (W) × height (H) (mm3). All injections and tumor 
measurement were performed under isoflurane anesthesia to 
minimize stress. 
To analyze the specific target accumulation of the imaging 
probes, mice were anesthetized by inhalation of isoflurane. 
Trastuzumab molecules (100ug) and affibody molecules (50ug) 
were injected into the tail vein and imaged by time point after 
injection (n = 5 / each group, n = 2 in control). At the end-point of 
experiments, all mice was sacrificed, and an autopsy was conducted 
to collect the primary tumors and fixed in 10% neutral buffered 
formalin solution (Sigma-Aldrich, MO, USA) for 12-24h and 
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paraffin-embedded and pathologically checked by hematoxylin and 
eosin (H&E) staining. 
Fluorescence intensity was captured using Lumina II IVIS 
system (Perkin Elmer, USA) and NIR-camera camera (InTheSmart, 
Seoul, Korea). All images proceeded with IVIS were quantified 
using Living image 2.50.1(Perkin Elmer, USA) and laparoscopic 
near-infrared camera images were analyzed by Image 
J(http://rsb.info.nih.gov/ij/; public comain free software developed by 
National Institutes of Health) This animal experiment was approved 
by the Institutional Animal Care and Use Committee(IACUC) of 




Mice were injected with 50 μg of 111In-NOTA-Affibody. 5 
min and 1 and 4 hours after injection, mice were scanned on an 
animal SPECT/CT device, using a 1.0-mm-diameter pinhole rat 
collimator cylinder. SPECT scans were acquired for 45 min (1 h 
after injection) or 60 min (4 h after injection), followed by CT 
scans for anatomic reference. Scans were reconstructed with 
VivoQuant reconstruction software (Invicro, MA, USA). 
Staining cancer specific probe to fresh tissue
We obtained SNU-601 and NCI-N87 solid tumor from 
mouse xenograft model. Trastuzumab-IRDye800CW (80ug) and 
affibody-IRDye800CW (40ug) were sprayed to gastric cancer cell 
derived isolated tumor. We applied each molecule for 5, 30 and 45
min to tumors. After washing the probes, we took fluorescence 
images using Lumina II IVIS system.
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Histology and immunohistochemistry
For histological analysis, the formalin-fixed paraffin-
embedded (FFPE) tissues were sectioned at a thickness of about 
4um, stained with hematoxylin and eosin (H&E) using Image Scope 
(Aperio, Leica Biosystems, USA), and immunohistochemistry (IHC) 
was carried out by the department of pathology at Seoul National 
University Hospital.
Statistical analysis
Student’s t-test was used to compare gene expression 
and paired t-test was used to test cell proliferation. Wilcoxon 
signed-rank test and Mann-Whitney test was were performed 
using GraphPad PRISM version 8.0.0 (GraphPad Software, San 
Diego, CA, USA). All data were presented as means ± standard 
deviation (SD). Statistical significance was defined as two-sided 
p-values P < 0.05.
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Results
Expression level of HER2 in gastric cancer 
We examined gene expression of ErbB2 in four gastric 
cancer cell lines, NCI-N87, SNU-601, SNU-620, SNU-638 by 
quantitative real-time PCR (Fig. 1A). Significant differences in the 
expression of HER2 was quantified by normalizing to the 
expression of GAPDH housekeeping gene. NCI-N87 and SNU-601 
showed remarkably high and low expression of ErbB2. 
Expression of HER2 and GAPDH as determined by western blotting 
of cultured cell lysates. Based on this, we selected NCI-N87 and 
SNU-601 as HER2 positive and negative. (Fig.1B) 
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Figure 1. HER2 expression of gastric cancer cell line
A, HER2 mRNA level of gastric cancer cell line B, HER2 protein level of 
gastric cancer cell line
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Fluorescence conjugation of the HER2-specific 
peptide
To ensure that the HER2-target peptide, trastuzumab and 
affibody, retained its ability to bind HER2/neu receptor, surface 
plasmon resonance (SPR) was performed. 
Trastuzumab-IRDye800CW and affibody-IRDye800CW 
were successfully synthesized with click mechanism (Fig. 2A) The 
efficiency of conjugation of IRDye800CW to both trastuzumab and 
affibody were determined based on absorbance measurements using 
a Varioskan LUX (Thermofisher, USA) at a different emission 
wavelength spectrum. There were no big difference in absorbance 
between Trastuzumab-IRDye800 and Affibody-IRDye800. (Fig. 
2B)
Trastuzumab molecules were analyzed by Reichert. (Fig. 2C, 
Supplementary Table. 1A) ErbB2 was immobilized at the 1,100
relative unit (RU) in the sample channel (Supplementary Table. 1B). 
Scrubber2 analysis software was used to obtain the equilibrium 
dissociation rate constant between ligand (ErbB2) and analyte 
(trastuzumab, trastuzumab-DBCO, trastuzumab-DBCO-
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IRDye800CW). Data were entered into 1:1 kinetic binding model 
and the values of Ka(M-1s-1), Kd(s-1), KD (nM) were calculate 
(Table 2).
Binding affinity of Affibody molecules was performed with 
Biacore. (Fig. 2D, supplementary Table.1b) BIAevaluation analysis 
software was used to obtain the equilibrium dissociation rate 
constant between ligand (ErbB2) and analyte (affibody, affibody-
DBCO, affibody-DBCO-IRDye800CW). Data were entered into 1:1 
kinetic binding model and the values of Ka, Kd, KD were calculate 
(Table2). The binding affinity level of trastuzumab-dye is higher 
than trastuzumab itself. However, affibody-dye affinity of HER2 










Figure 2. Binding affinity of the conjugates 
A, Structure of Trastuzumab-IRDye800CW and Affibody-
IRDye800CW B. Absorbance spectrum of Trastuzumab-IRDye800CW
and Affibody-IRDye800CW C, Binding affinity result of trastuzumab 
conjugated with IRDye800CW D, SPR result of HER2-target-affibody 
conjugated with IRDye800CW
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Supplementary Table 1A. Immobilization of ErbB2 for binding assay 
of trastuzumab molecules
Ligand Concentration Immobilization 
buffer
Flow rate Immobilization 
level







Supplementary Table 1B. Immobilization of ErbB2 for binding assay 
of affibody molecules
Ligand Concentration Immobilization 
buffer
Flow rate Immobilization 
level






Supplementary 1. Immobilization of ErbB2 for binding assay 
Immobilizing a Protein on a sensor chip for Surface Plasmon Resonance 
of A, trastuzumab conjugates and B. affibody conjugates
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Supplementary Figure 1. Binding affinity of the conjugates 
SPR result of A, Trastuzumab B. Trastuzumab-DBCO C, Affibody D,
Affibody-DBCO
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HER2 Unlabeled Affibody 3.10E+04 4.38E-
05 
1.42E-09 





1.36E+04   6.40E-
05
4.71E-09 
Table 2. Equilibrium dissociation constant of molecules
Binding assay result of modified molecules compared to unlabeled 
antibody and affibody
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Confocal microscopy experiments were performed to further 
investigate the binding specificities and patterns of the conjugates. 
Remarkable HER2 expression was shown with trastuzumab-
IRDye800CW in the cytoplasm together with cell surface was 
observed in NCI-N87 cells. (Fig.3A) On the other hand, affibody-







Figure 3. Confocal microscopy of gastric cancer cell line 
A, Intracellular image of gastric cancer cell with treating 1mM of 
Trastuzumab-IRDye800 and incubated 1 day imaged by 
LSM800(Zeiss) B, Intracellular image of gastric cancer cell with 
treating high dose of trastuzumab before applying 1mM of 
Trastuzumab-IRDye800 with HCS(Molecular Devices, USA)
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Cellular toxicity of trastuzumab and affibody 
molecules
To evaluate the toxicity of HER2-specific probes, their 
effects on cell proliferation was assessed. Two cancer cell lines 
NCI-N87 and SNU-601 were grouped as (1)Trastuzumab treated 
(2) Trastuzumab-IRDye800CW treated (3) Affibody-
IRDye800CW treated (4) Control and incubated for 48 hours. The 
conjugated molecules without Trastuzumab-IRDye800CW did not 
inhibit NCI-N87 cell growth and proliferation in any concentration 
of 10uM conjugates. Trastuzumab and trastuzumab-IRDye800CW
as well as affibody did not induce any significant effect on HER2-



































Figure 4. Cell Proliferation assay 
Each cancer cell line was applied 10uM of substances, incubated 2 days 
and measured cell viability. The absorbance of 450nm was measured at 
48hr in SNU-601 (A) and NCI-N87(B)
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NIR fluorescent imaging of tumors 
IRDye800CW conjugated trastuzumab and affibody were 
tested as NIR probe for in vivo optical imaging using mouse 
xenografts. Images of mouse whole body were measure by charge-
coupled device camera Lumina II IVIS system and NIR-camera
camera at different time points after tail vein injection of the 
trastuzumab-IRDye800CW, affibody-IRDye800CW (Fig. 5A). Mice 
injected with the trastuzumab-IRDye800CW showed less 
fluorescence intensities at first around the tumor and liver, until 
24hr time point. Localization of the signal intensities after 24 hours 
and peaked around 48 hours. After that, the signals from the tumor 
area lasted up to 3 days, while slowly growing weaker (Fig. 5B).
Signal-to-background ratios of each probe were calculated by 
normalizing signals from tumor area to those from normal tissue 
area. (Fig. 5C-5E) Specificity of HER2 imaging analysis shows by 
the experiments with HER2-nonexpressing SNU-601 tumors. The 
fluorescence intensities from each isolated tissue were also 
measured by Lumina II IVIS. (Fig. 5F)
42
Daily imaging of the HER2 positive and negative tumors after 
administration of trastuzumab-IRDye800CW showed that peak 
tumor background ratio(TBR)s for NIR-camera camera occurred 
2-day post injection. (Fig. 5G) Additionally, after 3 days, we 
sacrifice mice and harvest tumor, liver, kidney and spleen to how 
signal works in ex vivo. A statistically significant difference (24hr; 
P=0.002456, 48hr; P=0.000413, 72hr; P=0.000994, after sacrifice; 
P=0.000701) was noted between HER2 positive and negative tumor. 
(Fig. 5H) We measured gray scale of the signal by ImageJ software. 
After injecting trastuzumab-IRDye800CW intravenously, HER2 
positive solid tumor showed significantly higher signal than those in 
HER2 negative tumor (24hr; P=0.023817, 48hr; P=0.000337, 72; 
P=001438) The peak time of the signal of HER2 positive tumor 






































































Figure 5. NIR fluorescence imaging of trastuzumab-IRDye800 
A, the overall scheme for imaging of mouse xenograft model. B, mouse 
image of 1-3days after injected with trastuzumab-IRDye800CW C, Ex
vivo NIR image of sacrificed mice D-F, fluorescence intensity of tumor, 
liver, spleen (biodistribution) G, obtained image of NIR-camera camera 
at different time points H, NIR fluorescence of ex vivo image I,








Figure 6. Staining of NIR fluorescence  
A, the overall scheme for imaging of stained frozen tissue. B, IVIS 
image of trastuzumab-IRDye800CW stained tumor for 5min, 30min, 
45min. C, IVIS image of affibody-IRDye800CW stained tumor for 5min, 
30min, 45min.
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Imaging of the HER2 positive and negative tumors was also 
performed after administration of affibody-dye. Data showed that 
peak TBRs for NIR- camera occurred in 30min post injection. (Fig. 
7A) Additionally, after 1 hour, the signal of tumor was all gone, but 
high fluorescence intensity was shown at kidney and bladder. (Fig. 
7A) After 2days, we sacrifice mice and harvest tumor, liver, kidney 
and spleen to how signal works in ex vivo. (Fig. 7B) To determine 
if the affibody-dye binds to HER2 protein and to see how long it 
will wash out, department of Nuclear Medicine Chemistry labeled 








Figure 7. NIR fluorescence imaging of affibody-IRDye800CW
A, 30min and 1hour after injection of probe, slight signal is shown and 
washed out immediately B, Ex vivo NIR image of sacrificed mice
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Supplementary Fig. 2
. Supplementary Figure 2. To validate circulation of affibody in mice,  
SPECT/CT was performed to follow up radioisotope simultaneously. 
However, no signal of HER2 positive tumor.
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Histology and immunohistochemistry
To confirm HER2 expression level of extracted tumor from 
mice, we extracted tumor 72 hours after probe injection and 
performed immunohistochemistry analysis. Harvested tumor from 
mice bearing NCI-N87 showed positive membrane staining for 
anti-HER2 antibodies, while SNU-601 showed very weak or no 
membrane signal. (Fig. 8) This suggest that although tumor express 
high level of HER2, the very small molecule, affibody-dye, may not 
well-attached to protein.
Fig. 8
Figure 8. Immunohistochemistry and Haematoxylin & Eosin(H&E) staining  
Histological observations of the SNU-601 and NCI-N87 tumors. (x100)
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Discussion
Molecular imaging has been widely used as a tool for 
biological understanding, which focuses on the management of 
patients through the utilization of tracers in conjugation with 
imaging technologies. Recently people are trying to establish non-
invasive, specific, sensitive, quantitative, and cost-effective real-
time NIR-optical imaging techniques.(36) Applying fluorescence-
labeled tumor targeting molecules to patient’s tissue, surgeons can 
discriminate the lesion more safe and easily, so that they can detect
tumor cells and will be well-guided to dissect margins of tumor.(37, 
38)
There is growing evidence that HER2 is an important 
biomarker in gastric cancer, with studies showing amplification or 
overexpression in 7-34% of tumors. HER2 3+ at IHC and FISH 
amplified or HER2 score 2+ at IHC and FISH amplified are HER2 
positive in gastric cancer.
Among various imaging agents, indocyanine green (ICG), 
which absorbs light at 780nm to 820nm, is used to evaluate blood 
flow, liver function assessment and map the lymph node vessels.(39)
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However, ICG is rapidly dispersed and degraded in a aqueous 
conditions with low tissue penetration. IRDye800CW shows less 
non-specific binding, dispersion time and can bind biomolecules
more than ICG. Although IRDye800CW has not been FDA approved, 
it has a drug master file with FDA and is safe at doses of 20mg/kg, 
IRDye800CW can be a promising future near-infrared fluorophore 
and alternative of ICG. (40, 41),
Since molecular imaging is a non-invasive procedure, it 
may have an advantage over biopsy-based approaches and has 
potential to help guide physicians to tailor treatment for patients.
Various kinds of antibody or antibody fragments were now 
engineered. One of the antibody segments, affibody is very small 
proteins (6-7 kDa) while general IgG is 150kDa. This protein has
been reported in many studies with high water-solubility, high 
stability α-helical proteins. Since the size of affibody is very small 
compare to antibody, we hypothesized that HER2-specific affibody 
conjugated with IRDye800CW can visualize tumor better than 
HER2-specific antibody conjugated with IRDye800CW. In this 
study, we aimed to visualize HER2 expression in gastric cancer and 
compare which fluorescent-labeled HER2 tracer work efficiently.
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Many studies had shown HER2 expression of gastric cancer 
cell lines. (42, 43) The HER2 expressing human gastric cancer cell 
line NCI-N87 and SNU-601 has been selected and used for tumor 
xenograft in mice (Fig. 1) The fluorescence intensity of conjugated 
molecules were observed at different wavelength. The intensity 
was highest at a 800nm emission filter. (Fig. 2B) Before 
investigating in vivo binding to these cells, it was necessary to first 
study the in vitro binding. The kinetics observed was similar to both 
unlabeled HER2 target peptides. (Fig. 2C,D) Our data from confocal 
microscopy showed that trastuzumab-IRDye800CW is significantly 
internalized into HER2 positive cell. (Fig. 3) Through cell 
proliferation assay, attaching fluorescence or not had no significant 
effect on the cancer cells. (Fig. 4) Our results agree with previous 
findings on cellular toxicity and intracellular signaling, supporting 
that the probe does not affect the system to be studied. (Fig. 3 and 
Fig. 4)
It has been well documented that conjugation chemistry 
using an azide group to react with an alkyne is an efficient method 
of conjugation. As shown in Table2, modification of the trastuzumab 
with IRDye800CW azide dyes resulted in increased affinity, but 
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affibody modification is resulted in a slight reduction of the affinity 
of the conjugates. Affibody binds to domain III of HER2 while 
trastuzumab binds to domain IV of HER2(44).
There are several optical methods and systems in clinically 
use today where light can penetrate into the tissue. In this study, 
we used optical imaging system presented for preclinical studies on 
small animal, IVIS system and NIR-camera. (Fig. 5) The novelty of 
our study is that we used an actual NIR-camera camera to visualize 
HER2 in gastric cancer by the different distance between the tumor 
and camera. (Fig. 5G) As affibody does not access to the same 
epitope as trastuzumab, this molecule can be used to monitor HER2 
receptor expression during Trastuzumab treatment. However, 
although the affibody was expected to be clinically usable in the 
future due to its small size and good circulation in the body, it 
seemed to be inadequate in mouse model because of rapid renal 
clearance (Fig. 7, Supplementary Fig. 2), suggesting the small size 
of the protein injected in vivo does not seem to visualize tumor 
successfully.
In a preclinical setting, NIR fluorescence-labeled antibodies 
targeting HER2 allowed to specificity and sensitivity of detection of 
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tumor in vivo. These findings strongly suggest that the NIR-
fluorescence-labeled anti-cancer tracer can be used in a clinical 
application, including intraoperative image-guided surgery. This 
may give us new approaches in the diagnosis or treatment of 
HER2-positive in gastric cancer. Although further studies are 
needed to investigate efficacy of the synthesized molecules, non-
invasive procedure for cancer specific imaging can provide a tool 
for optimization or characterization of HER2 in patients or guidance 
where to dissect. 
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국문 초록
배경: 영상을 기반으로 하는 진단과 수술은 광범위하게 사용되고 있는데, 그 중
근적외선 (NIR) 기반의 형광 이미징이 수술 중 혹은 내시경 중에 그 활용도가
매우 높다. 표적 항체와 작은 펩타이드를 이용하여 종양을 영상화 하는 연구가
활발히 진행되고 있으며 이는 전임상 및 임상에서 적용되고 있다. 인체에
주입할 수 있는 형광물질인 indocyaninegreen(ICG)는 특이적으로 종양을
표지 할 수 없으며, 주입 후 금방 퍼지는 단점이 있다. 또한 ICG 는 액체
상태에서는 매우 불안정 하며, 금방 퍼지기 때문에 주변 형광 신호가 함께
표지된다. 반면, 근적외선 형광 IRDye800CW 는 ICG 보다 수용성에서 훨씬
안정적이며 주변 비특이적 형광신호가 적게 보인다는 장점이 있다. HER2 는
세포의 표면에 발현하고 있는 단백질로써 위암을 비롯한 많은 종류의 암에서
과발현시, 안 좋은 예후를 보인다. 특정 분자를 타겟하는 단백질 및 항체와
항체의 일부 조각들이 많이 발견되고 엔지니어링되었다. HER2 에 특이적으로
부착할 수 있는 단백질 중 HER2 의 서로 다른 위치에 붙는
antibody(trastuzumab)과 affibody 를 이용한 연구가 활발히 되어있다. 
목적 : 본 연구는 IRDye800CW 와 HER2 에 단일 항체 trastuzumab 과 6-
7kDa 정도의 사이즈인 affibody 를 부착하여 HER2 를 생체 내 정량 할 수
있는 도구로써의 분자 프로브를 개발하고 각각을 비교하며, 이를 소동물
근적외선 카메라와 실제 수술장에서 사용되고 있는 복강경 카메라를 사용하여
마우스 위종양모델에서 영상화하고 그 효용성을 확인하고자 한다. 
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방법: 본 연구팀에서는 HER2 발현 수준에 따라 인간 위암 세포주 NCI-N87, 
SNU601 을 사용하여 실험을 진행하였다. HER2 단일 항체인 trastuzumab 과
작은 단백질 구조를 가지고 있는 affibody 를 근적외선 형광인 IRDye800 에
합성하여 HER2 단백질에 부착하는 정도와 특성화도를 표면 플라즈몬 공명
(SPR)을 통하여 확인했다. 합성된 표적 프로브로 세포주를 형광 촬영하였으며
Trastuzumab-dye 의 효용성을 보기 위하여 각 세포주는 암컷 BALB/c-nu 
마우스 피하에 주입하여 2-3 주간 종양 형성을 관찰하였고 부피가 200-
300(mm
3
)에 이르렀을 때, 소동물 영상 장비인 IVIS 와 복강경 카메라를
이용하여 형광을 영상화 하였다. Affibody-dye 가 생체 내에서 HER2 를
효과적으로 영상할 수 있는지를 보기 위하여 trastuzumab-dye 모델과
마찬가지로 각 세포주를 암컷 BALB/c-nu 피하에 주입 후 종양의 부피가
200-300(mm3)에 이르렀을 때, 소동물 영상장비로 형광을 확인하였다. 
Affibody-dye 를 마우스에 주입 후 해당 물질이 종양에 도달하기까지 얼마의
시간이 필요한지 확인하기 위하여 HER2 양성 세포주 마우스모델에 affibody-
In 을 소동물 SPECT/CT 를 이용하여 보았다. 형광 영상이 끝난 모든
마우스에서 종양과 다른 부위의 장기를 적출하여 포르말린에 고정시켜 파라핀
블록으로 만들어 Hematoxylin & Eosin (H&E) 염색과 면역조직화학염색법을
진행하여 암 조직의 HER2 발현과 분자적 특징을 확인하였다. 
결과: 표면 플라즈몬 공명에서 합성된 trastuzumab-dye 는 trastuzumab 보다
높은 친화도를 보였으며, affibody-dye 는 affibody 보다 낮은 친화도를 보였다. 
Trastuzumab-dye 를 각 HER2 양성 및 음성 세포주에 염색하였을 때, 둘 다
형광이 보이긴 하였으나 HER2 과발현 되어있는 NCI-N87 에서 그 신호가
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매우 셌음을 확인할 수 있었다. IVIS 와 복강경 카메라를 이용한 trastuzumab-
dye 영상은 HER2 음성 위암 세포 마우스 모델에서보다 양성 위암 세포
마우스 모델의 종양에서 유의하게 높은 신호를 보였으며, HER2 음성
그룹에서는 신호 저해가 보이지 않거나 상당히 낮았다. 반면, affibody-dye 
영상은 마우스 꼬리 정맥에 주사 후 약 30 분 ~ 1 시간 내에 신장으로 물질이
갔으며 이는 IVIS system 에서 확인할 수 있었다. 체내 순환을 확인하기
위하여 affibody 에 방사선 동위원소인 In 를 부착하여 시간 별로 영상을
촬영해보았으나 신장으로 대부분의 형광이 갔음을 확인할 수 있었다. 
결론: 본 연구를 통해 IRDye800CW 와 결합 된 trastuzumab 이 전임상적으로
과발현 되어있는 HER2 종양을 모니터링 할 수 있는 도구가 될 수 있음을
보였다. 크기가 매우 작은 affibody 는 체내 순환이 빠르고 HER2 단백질에서
trastuzumab 과 다른 위치에 부착한다는 이점을 바탕으로 전임상적인 효과가
뛰어날 것으로 예상하였지만 마우스에서는 그 효용성이 낮음을 확인하였다. 더
많은 연구가 진행되어야 할 것으로 보이나 두 물질은 향후 위암 환자에서
조직검사를 하기 앞서 HER2 발현을 평가하기위한 보완적인 수단을 제공할 수
있을 것이다. 또한 이 물질은 영상 유도 수술 중 HER2 양성 병변을 추가로
탐지하는 데 활용될 수 있을 것이다.
………………………………………………………………………………………………
…………………
주요어: 위암, HER2, Trastuzumab, Affibody, 종양 표적 추적자, 근적외선
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